
LY2157299
CAS No. 700874-72-2
LY2157299 ( Galunisertib | LY-2157299 | LY 2157299 )
产品货号. M15689 CAS No. 700874-72-2
LY2157299 (Galunisertib) 是一种有效、特异性的 TGF-β 受体 I 激酶 ((TGF-βRI)) 抑制剂,IC50 为 56 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥324 | 有现货 |
![]() ![]() |
10MG | ¥405 | 有现货 |
![]() ![]() |
50MG | ¥996 | 有现货 |
![]() ![]() |
100MG | ¥1604 | 有现货 |
![]() ![]() |
200MG | ¥2414 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称LY2157299
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述LY2157299 (Galunisertib) 是一种有效、特异性的 TGF-β 受体 I 激酶 ((TGF-βRI)) 抑制剂,IC50 为 56 nM。
-
产品描述LY2157299 (Galunisertib) is a potent, specific inhibitor of TGF-β receptor I kinase ((TGF-βRI) with IC50 of 56 nM; inhibits TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner, stimulates hematopoiesis from primary MDS bone marrow specimens; ameliorates anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure; displays significant antitumor activity against both Calu6 and MX1 xenografts in mice.Blood Cancer Phase 3 Clinical(In Vitro):Galunisertib (LY2157299) (0.1, 1, 10, and 100 μM) displays a slight dose-dependent potentiation of Bay 43-9006 in SK-Sora, HepG2, and Hep3B cell lines but not in JHH6, SK-HEP1, and HuH7 cell lines.(In Vivo):Human xenografts Calu6 (non-small cell lung cancer) and MX1 (breast cancer) are implanted subcutaneously in nude mice. After oral administration of 75 mg/kg, Galunisertib (LY2157299) induces a 70% decrease in pSmad for both types of cell lines. The time at which pSmad recovered 80% of baseline is approximately 6 h after administration.
-
体外实验Galunisertib (LY2157299) (0.1, 1, 10, and 100 μM) displays a slight dose-dependent potentiation of Bay 43-9006 in SK-Sora, HepG2, and Hep3B cell lines but not in JHH6, SK-HEP1, and HuH7 cell lines.
-
体内实验Human xenografts Calu6 (non-small cell lung cancer) and MX1 (breast cancer) are implanted subcutaneously in nude mice. After oral administration of 75 mg/kg, Galunisertib (LY2157299) induces a 70% decrease in pSmad for both types of cell lines. The time at which pSmad recovered 80% of baseline is approximately 6 h after administration.
-
同义词Galunisertib | LY-2157299 | LY 2157299
-
通路TGF-beta/Smad
-
靶点TGFBR
-
受体TβRI
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number700874-72-2
-
分子量369.4192
-
分子式C22H19N5O
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 47 mg/mL
-
SMILESO=C(C1=CC=C2N=CC=C(C3=C(CCC4)N4N=C3C5=NC(C)=CC=C5)C2=C1)N
-
化学全称6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Zhou L, et al. Cancer Res. 2011 Feb 1;71(3):955-63.
2. Yoon JH, et al. EMBO Mol Med. 2013 Nov;5(11):1720-39.
3. Bhola NE, et al. J Clin Invest. 2013 Mar;123(3):1348-58.
4. Rodon J, et al. Clin Cancer Res. 2015 Feb 1;21(3):553-60.